TH17 cells are a potential therapeutic target in autoimmune arthritis
This article has no abstract so we have provided the first paragraph of the full text.
In autoimmune arthritis, activated type 1 T helper (TH1) lymphocytes were previously thought to cause bone destruction mediated by osteoclasts. Paradoxically, however, TH1 lymphocytes produce interferon-
, which inhibits osteoclastogenesis. Bone destruction might, therefore, be attributable to a different subset of CD4+ TH cells, with a specific cytokine profile. Sato and colleagues explored the effects of various T-cell subsets on osteoclast differentiation, and found that interleukin-(IL)-17-producing CD4+ TH cells (TH17 cells) were the only osteoclastogenic T-cell lineage characterized to date.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
